[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353341-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353341-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeted-nanotherapeutic-strategy-for-melanoma-using-silk-fibroin-based-artemisinin-nanoparticles","Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles","","Malignant melanoma is an aggressive, life-threatening skin cancer that often spreads rapidly and may not respond adequately to standard therapies. A targeted nanotherapeutic approach was developed using spherical silk fibroin-stabilised artemisinin nanoparticles (SF-ARTNPs). The nanoparticles showed enhanced stability, improved aqueous dispersibility, high drug-loading efficiency (86.27 ± 2.05%), and sustained drug release (84.60 ± 7.29%). In vitro studies demonstrated strong anti-melanoma activity against A375 cells, with viability reduced to 23.31 ± 4.62% at 40 mg mL−1, supported by suppressed migration in scratch assays. These results indicate SF-ARTNPs as an effective platform for treating malignant melanoma.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeted-nanotherapeutic-strategy-for-melanoma-using-silk-fibroin-based-artemisinin-nanoparticles/353341/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeted-nanotherapeutic-strategy-for-melanoma-using-silk-fibroin-based-artemisinin-nanoparticles/353341.png","ImageObject",300,407,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are targeted nanotherapeutic strategies needed for melanoma?","Question",{"text":63,"@type":64},"Melanoma can spread quickly and may not respond well to standard treatments. High costs and limited bioavailability of existing immunotherapy and targeted therapy can further drive the need for improved delivery systems.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were silk fibroin-stabilised artemisinin nanoparticles used for in this study?",{"text":68,"@type":64},"They were synthesized as a nanotherapeutic platform and evaluated for anti-melanoma efficacy, focusing on stability, drug loading, sustained release, and anti-cancer effects in vitro.",{"name":70,"@type":61,"acceptedAnswer":71},"What anti-melanoma effects were observed in vitro?",{"text":72,"@type":64},"SF-ARTNPs significantly reduced the viability of A375 melanoma cells to 23.31 ± 4.62% at 40 mg mL−1. Scratch assays also indicated suppressed cell migration.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353341,1790216222,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","RSC Advances  \nPAPER  \nPublished on 11 August 2026 Licensed under CC-BY-NC 4.0  \nCite this: DOI: 10 .1039/d6ra04405k  \nReceived 20th May 2026  \nAccepted 30th July 2026  \nDOI: 10.1039/d6ra04405k[rsc.li/rsc-advances](rsc.li/rsc-advances)  \nTargeted nanotherapeutic strategy for melanoma using silk-ﬁbroin based artemisinin nanoparticles  \nDeepinder Sharda,ab Amanpreet Kaur, bc Arnab Pattanayakc and Diptiman Choudhury  *ab  \nSkin cancer is one of the most common cancers in the world, and malignant melanoma is the most aggressive and life-threatening form of skin cancer. It often quickly spreads to other parts of the body and may not always respond well to standard treatments. This calls for the urgent development of moreeﬀective and targeted treatment strategies. Protein-based nanoparticles have gained considerable attention in oncology owing to their improved bioavailability, tumour-targeted delivery potential, and reduced systemic toxicity. Silk ﬁbroin, a versatile natural biopolymer, has emerged as a promising drugdelivery platform because of its excellent biocompatibility, biodegradability, and structural adaptability. In the present study, spherical silk ﬁbroin-stabilised artemisinin nanoparticles (SF-ARTNPs) were synthesised and evaluated for their anti-melanoma eﬃcacy. The developed nanoparticles demonstrated enhanced stability, improved aqueous dispersibility, high drug-loading eﬃciency (86 .27 ± 2. 05%), and a sustained drug-release proﬁle (84 .60 ± 7. 29%) . In vitro cytotoxicity studies revealed that SF-ARTNPs signiﬁcantly reduced the viability of A375 melanoma cells to 23 .31 ± 4. 62% at a concentration of 40 mg mL −1, which is further corroborated by scratch assay results indicating suppressed cell migration. Collectively, these ﬁndings suggest that SF-ARTNPs have strong potential as an eﬀective nanotherapeutic platform for treating malignant melanoma.  \n1. Introduction  \nSkin cancer, the 􀀁􀀁h most common form of cancer, remains a signi􀀁cant cause of fatality globally, despite the ongoing innovation of the latest techniques, therapies, and medications for its diagnosis and treatment.1–3 The highest incidence rate isin Australia, at 37 cases per 100 000 persons, followed by 31.10 cases per 100 000 in Denmark and 30.60 cases per 100 000 in Norway. Europe accounts for 10.40 cases.4 A report by the American Academy of Dermatology indicates that nearly 9500 people are diagnosed with skin cancer every day alone in the USA.5 The statistics of the American Cancer Society point out that new melanoma cases among all cancers were found to be 6% in males and 4% in females in 2023, and the number of new cases is expected to grow over the next two decades.6 The prolonged exposure to chemical carcinogens and UV radiation, along with genetic mutations, suppression of the immune system, etc., is the primary cause of this ailment.7,8 The  \naDepartment of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala, 147004, Punjab, India. E-mail: [diptiman@thapar.edu](diptiman@thapar.edu); Tel:+91-8196949843  \nbThapar Institute of Engineering and Technology-Virginia Tech (USA), Center of Excellence in Emerging Materials, Thapar Institute of Engineering and Technology, Patiala, Punjab-147004, India  \ncDepartment of Electronics and Communication Engineering, Thapar Institute of Engineering and Technology, Patiala, 147004, Punjab, India  \nmechanism involves uncontrolled cell proliferation facilitated by UV-radiation-induced DNA damage, causing mutations or genetic defects through strand breaks and nucleobase alterations, which in turn lead to an imbalance between ROS (Reactive Oxygen Species) production and cellular antioxidant defence mechanisms.9  \nSkin cancer is categorised into melanoma (involves melanocytes) and non-melanoma (involves keratinocytes) based on cellular origin.10,11 Depending upon the type of cells involved, non-melanoma cancer (which accounts for 95% of cases) is categorised into Basal Cell Carcinom","cbCaitMJGSBGGEHX","https://ap.wps.com/l/cbCaitMJGSBGGEHX","pdf",1527380,14,"English","# Introduction\n## Skin cancer burden and causes\n## Classification of skin cancer\n## Diagnosis and treatment approaches\n## Limitations of current therapies\n## Need for natural anticancer agents\n## Role of artemisinin and related metabolites","[{\"question\":\"Why are targeted nanotherapeutic strategies needed for melanoma?\",\"answer\":\"Melanoma can spread quickly and may not respond well to standard treatments. High costs and limited bioavailability of existing immunotherapy and targeted therapy can further drive the need for improved delivery systems.\"},{\"question\":\"What were silk fibroin-stabilised artemisinin nanoparticles used for in this study?\",\"answer\":\"They were synthesized as a nanotherapeutic platform and evaluated for anti-melanoma efficacy, focusing on stability, drug loading, sustained release, and anti-cancer effects in vitro.\"},{\"question\":\"What anti-melanoma effects were observed in vitro?\",\"answer\":\"SF-ARTNPs significantly reduced the viability of A375 melanoma cells to 23.31 ± 4.62% at 40 mg mL−1. Scratch assays also indicated suppressed cell migration.\"}]","Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles | PDF",1790104807,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4971d9f2920cf0c4e02f0e7dd3aba7e0.webp",983,1287,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8656a8d048694af2f5a0f2689b5567f.webp",982,1286,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/742eb7340fd26f67dcb012cfc41c9d82.webp",981,1284,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1be5082cd96f06b3f3732b9627388a35.webp",980,1283]